Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority.
Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy.
H.R. 6, the "21st Century Cures Act.
H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act."
H.R. 2841, the "Fair Access for Safe and Timely Generics Act."
H.R. 1600, the "Patients' Access to Treatments Act."
H.R. 2739, the "Cancer Drug Coverage Parity Act."
S.1566, the "Cancer Drug Coverage Parity Act."
H.R. 3982, the "Family Cord Blood Banking Act."
H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.
H.R. 3982, the "Family Cord Blood Banking Act."
Policy issues relating to corporate tax reform.
Duration: April 27, 2012
to
May 31, 2016
General Issues: Health Issues , Copyright/Patent/Trademark , Taxation/Internal Revenue Code , Veterans , Trade (Domestic & Foreign)
Spending: about $560,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2012: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Chris Jones Chief of Staff/Rep. Mike Ferguson
Deputy Chief of Staff/Rep. David McIntosh
Communications Dir./House Govt. Reform and Oversight Subcmte
Press Secretary/Rep. John Myers
Adam Higgins Legislative Assistant/Rep. Mike Ferguson
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2016
Ferguson Strategies, LLC terminated an engagement in which they represented Celgene Corporation on July 19, 2016.
Original Filing: 300813766.xml
Lobbying Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority.
Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy.
H.R. 6, the "21st Century Cures Act.
H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act."
H.R. 2841, the "Fair Access for Safe and Timely Generics Act."
H.R. 1600, the "Patients' Access to Treatments Act."
H.R. 2739, the "Cancer Drug Coverage Parity Act."
S.1566, the "Cancer Drug Coverage Parity Act."
H.R. 3982, the "Family Cord Blood Banking Act."
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 3982, the "Family Cord Blood Banking Act."
Policy issues relating to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2016
In Q1, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $40,000. The report was filed on April 19, 2016.
Original Filing: 300794881.xml
Lobbying Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority.
Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy.
H.R. 6, the 21st Century Cures Act.
H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act.
H.R. 2841, the Fair Access for Safe and Timely Generics Act.
H.R. 1600, the Patients Access to Treatments Act.
H.R. 2739, the Cancer Drug Coverage Parity Act.
S.1566, the "Cancer Drug Coverage Parity Act."
H.R. 3982, the Family Cord Blood Banking Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 3982, the "Family Cord Blood Banking Act."
Policy issues relating to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2015
In Q4, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $40,000. The report was filed on Jan. 15, 2016.
Original Filing: 300772729.xml
Lobbying Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority.
Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases.
Policy issues relating to patient cost-sharing for specialty medicines.
H.R. 6, the 21st Century Cures Act.
H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act.
H.R. 2841, the Fair Access for Safe and Timely Generics Act.
H.R. 1600, the Patients Access to Treatments Act.
H.R. 2739, the Cancer Drug Coverage Parity Act.
H.R. 3982, the Family Cord Blood Banking Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
H.R. 3982, the "Family Cord Blood Banking Act."
Policy issues relating to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2015
In Q3, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $40,000. The report was filed on Oct. 19, 2015.
Original Filing: 300758267.xml
Lobbying Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority.
Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases.
Policy issues relating to patient cost-sharing for specialty medicines.
Policy issues relating to federal tax benefits for cord blood banking, placental blood banking and placental tissue banking services.
H.R. 6, the 21st Century Cures Act.
H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act.
H.R. 2841, the Fair Access for Safe and Timely Generics Act.
H.R. 1600, the Patients Access to Treatments Act.
H.R. 2739, the Cancer Drug Coverage Parity Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Policy issues relating to federal tax benefits for cord blood banking, placental blood banking and placental tissue banking services.
Policy issues relating to corporate tax reform.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2015
In Q2, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $40,000. The report was filed on July 17, 2015.
Original Filing: 300738609.xml
Lobbying Issues
Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act."
Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority.
Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases.
Policy issues relating to patient cost-sharing for specialty medicines.
Policy issues relating to tax benefits for cord blood banking, placental blood banking and placental tissue banking services.
H.R. 6, the 21st Century Cures Act.
H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act.
H.R. 2841, the Fair Access for Safe and Timely Generics Act.
H.R. 1600, the Patients Access to Treatments Act.
H.R. 2739, the Cancer Drug Coverage Parity Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Policy issues relating to tax benefits for cord blood banking, placental blood banking and placental tissue banking services.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2015
In Q1, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $40,000. The report was filed on April 20, 2015.
Original Filing: 300726402.xml
Lobbying Issues
21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry.
Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases.
H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act.
H.R. 2, the "Medicare Access and CHIP Reauthorization Act.
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program.
Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues.
Public Law No. 110-85, the "Food and Drug Administration Amendments Act," including current policy issues relating to FDA's Risk Evaluation and Mitigation Strategy authority.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2014
In Q4, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $40,000. The report was filed on Jan. 20, 2015.
Original Filing: 300702814.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program.
Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues.
Public Law No. 110-85, the "Food and Drug Administration Amendments Act," including current policy issues relating to FDA's Risk Evaluation and Mitigation Strategy authority.
H.R. 5657, the "Fair Access for Safe and Timely Generics Act."
H.R. 3230, the "Veterans' Access to Care through Choice, Accountability and Transparency Act."
H.R. 3116, the "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act."
Policy issues relating to orphan drugs and medicines for rare diseases.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2014
In Q3, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $40,000. The report was filed on Oct. 14, 2014.
Original Filing: 300676062.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program.
Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues.
Public Law No. 110-85, the "Food and Drug Administration Amendments Act," including current policy issues relating to FDA's Risk Evaluation and Mitigation Strategy authority.
H.R. 5657, the "Fair Access for Safe and Timely Generics Act."
H.R. 3230, the "Veterans' Access to Care through Choice, Accountability and Transparency Act."
H.R. 3116, the "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act."
Policy issues relating to orphan drugs and medicines for rare diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
H.R. 3230, the "Veterans' Access to Care through Choice, Accountability and Transparency Act."
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $40,000. The report was filed on July 15, 2014.
Original Filing: 300657239.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Prescription Drug User Fee program.
Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues.
Public Law No. 110-85, the "Food and Drug Administration Amendments Act," including current policy issues relating to FDA's Risk Evaluation and Mitigation Strategy authority.
H.R. 3230, the "Veterans' Access To Care Through Choice, Accountability and Transparency Act."
H.R. 3116, the "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act."
Policy issues relating to orphan drugs and medicines for rare diseases.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Policy issues regarding the U.S.-China Joint Commission on Commerce and Trade, including Article 26.3 of Chinese Patent Law and biopharmaceutical intellectual property.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
H.R. 3230, the "Veterans' Access to Care through Choice, Accountability and Transparency Act."
Agencies Lobbied
U.S. Senate
1st Quarter, 2014
In Q1, Ferguson Strategies, LLC lobbied for Celgene Corporation , earning $30,000. The report was filed on April 19, 2014.
Original Filing: 300642820.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program; policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act"; H.R. 3116, the "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act"; and policy issues relating to orphan drugs and medicines for rare diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Policy issues regarding the U.S.-China Joint Commission on Commerce and Trade, including Article 26.3 of Chinese Patent Law and biopharmaceutical intellectual property.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2013
In Q4, Ferguson Strategies LLC lobbied for Celgene Corporation , earning $30,000. The report was filed on Jan. 15, 2014.
Original Filing: 300614850.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program; policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act"; H.R. 3116, the "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act"; and policy issues relating to orphan drugs and medicines for rare diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Policy issues relating the U.S.-China Joint Commission on Commerce and Trade, including Article 26.3 of Chinese Patent Law and biopharmaceutical intellectual property.
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2013
In Q3, Ferguson Strategies LLC lobbied for Celgene Corporation , earning $30,000. The report was filed on Oct. 17, 2013.
Original Filing: 300596512.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program; policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act"; H.R. 3116, the "Modernizing Our Drug and Diagnostics Evaluation and Regulatory Network Cures Act"; and policy issues relating to orphan drugs and medicines for rare diseases.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2013
In Q2, Ferguson Strategies LLC lobbied for Celgene Corporation , earning $30,000. The report was filed on July 17, 2013.
Original Filing: 300573953.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program.
Policy issues relating to orphan drugs and medicines for rare diseases.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2013
In Q1, Ferguson Strategies LLC lobbied for Celgene Corporation , earning $30,000. The report was filed on April 19, 2013.
Original Filing: 300556405.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2012
In Q4, Ferguson Strategies LLC lobbied for Celgene Corporation , earning $20,000. The report was filed on Jan. 17, 2013.
Original Filing: 300532295.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2012
In Q3, Ferguson Strategies LLC lobbied for Celgene Corporation , earning $20,000. The report was filed on Oct. 19, 2012.
Original Filing: 300512124.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
In Q2, Ferguson Strategies LLC lobbied for Celgene Corporation , earning $20,000. The report was filed on July 19, 2012.
Original Filing: 300491034.xml
Lobbying Issues
Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2012
Ferguson Strategies LLC filed a lobbying registration on May 2, 2012 to represent Celgene Corporation, effective April 27, 2012.
Original Filing: 300477729.xml
Issue(s) they said they’d lobby about: Policy issues relating to reauthorization of the Prescription Drug User Fee Act and implementation of the Patient Protection and Affordable Care Act (Public Law 111-148). .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...